[Stock idea]: Marksans Pharma…Targeting 3000 crore sales in FY 26
Recently, while screening for stocks for our Premium Members, I came across Marksans Pharma. The stock is down from 350 odd levels to 190 currently. The company has reported consistent year on year growth in sales and is debt free on net basis with Rs 700 crore + cash. For FY 26, the management is targeting Rs 3,000 crore sales with 16-18% EBITDA margins. Below, we have shared notes from Q1 FY 26 concall of the company to understand management’s perspective…
